Crocs, Inc. (CROX): what the price requires

At today's price, Crocs, Inc. (CROX) is priced for +24.5% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Exported: 2026-07-20 · Source: https://boothcheck.com/report/CROX

Headline

FieldValue
TickerCROX
CompanyCrocs, Inc.
Current price$130.49/sh
CompositionCrocs Brand - Wholesale 40% / Crocs Brand - Direct-to-consumer 43% / HEYDUDE Brand - Wholesale 8% / HEYDUDE Brand - Direct-to-consumer 9%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed4.8%
Operating margin (mid-cycle)13.0%
Margin compression implied-8.2pp
Trailing margin (depressed year)5.1%
Implied growth24.5%
Multiple paid16x mid-cycle operating income

The operating-margin requirement is derived from the framework's value band at year 11, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 11.8% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~6.7pp.

Reconcile: at the x-ray's 9.3% required return this reads ~8.7%/yr; the models below use their own rates.

How unusual the bet is: within-range

ReferenceValue
vs own history-0.17σ
cohort percentile (of 141 peers)42
sustained it ~5 years at this level35%
implied end-window share0%

Valuation X-Ray

The price is supported by earnings-power and relative-multiple and growth-DCF value, while asset-based lands below the price. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset5.15x3expensive
Earnings1.24x3expensive
Relative0.66x3justifies
Growth1.06x3expensive

Families that justify the price: Earnings, Relative, Growth Families that call it expensive: Asset

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.5%); the inversion above states its own rate.

Per-Model Detail (n=12)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$123.641.06xyesFCF base $0.6B, growth -2% (input: historical growth), terminal g 0.5%, WACC 7.5%, 5yr projection
DCF Exit MultipleGrowth$131.320.99xyesExit EV/EBITDA: 37.4x / 39.4x / 41.4x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelative$198.430.66xyesP/S fallback (negative EPS): Sector P/S 2.5x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$28.154.64xyesReference only (book value floor): BV/sh $28.15, ROE negative
Two-Stage Excess ReturnAsset$25.335.15xyesReference only (book value with convergence): BV/sh $28.15, ROE converges to ke
Discounted Future Market CapGrowth$71.501.83xyesRev $4.0B, growth -2% (input: historical growth; tapered), Terminal P/S: 1.4x / 1.6x / 1.9x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$140.410.93xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.92B × (1−23%) / WACC 7.5% → EPV (no growth)
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative$17.867.31xyesEBITDA $0.21B × sector EV/EBITDA 12.0x
FCF YieldEarnings$105.621.24xyesFCF $642.9M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$97.401.34xyesSBC-adj FCF $0.60B (FCF $0.64B − SBC $0.04B) capitalized at Kₑ
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset$19.126.82xyesBV $28.15 × (ROIC 5.1% / WACC 7.5%)
P/Sales SectorRelative$198.430.66xyesRevenue $4.02B × sector P/S 2.5x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$1.2b
Net debt / NOPAT (after-tax)3.02x
Net debt / operating income (pre-tax)2.32x
Interest coverage5.9x
Share count CAGR (buyback)-4.5%
Burning cashno

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 13.0%); the trailing year was depressed.

Bullet Takeaways

Bull Case

Look first at what Crocs does with its cash, because it tells you how management reads its own business. The company generates around $640 million of free cash flow a year, and it is using that cash to retire stock aggressively, shrinking the share count about 4.5% annually and repurchasing roughly $74 million more in the period after the first quarter. A management team buying back this much stock while the multiple is compressed is making a bet that the market is undervaluing the cash the business throws off. With the stock trading at a single-digit forward earnings multiple, every dollar of buyback retires far more earnings power than it would at a sector multiple.

The core franchise behind the cash is healthier than the consolidated numbers suggest. The Crocs brand, roughly four-fifths of revenue, is built on a small set of durable product pillars, the clog, the sandal, and the Jibbitz charms that personalize them, and it is growing where the growth is: international Crocs brand revenue rose 7% in the first quarter even as North America fell 6%. Management expects international revenue to surpass North America in 2026 on about 10% international growth, with China a standout, supported by up to 250 new stores worldwide. A brand that can grow abroad while its home market matures has a longer runway than the consolidated decline implies.

The HEYDUDE turnaround is the call-option on top of the core. HEYDUDE has been the drag, but the reset is showing early signs of working: direct-to-consumer revenue for the brand rose 8% in the first quarter, and management improved its full-year HEYDUDE guidance to a 5% to 7% decline from a steeper drop. The brand's value has already been written down hard, so the bull case does not need HEYDUDE to be brilliant. It needs HEYDUDE to stop bleeding, which lets the depressed consolidated margin revert toward the company's through-the-cycle level. The bull case is a cash machine in its core brand, an international growth runway, and a second brand whose worst is likely behind it, all priced as if the trough is permanent.

Bear Case

The bear case is a question about where Crocs sits in the footwear cycle, and the company itself supplies the warning. In its own filings it notes that footwear companies "including ours, have experienced periods of rapid growth in revenues and earnings followed by periods of declining revenues and losses, and our business may be similarly affected in the future." That is the structural risk in plain language: a brand built on a distinctive product can ride a wave of popularity and then face the downslope when the wave passes. The Crocs clog is a genuine cultural product, but cultural products are not guaranteed to compound, and the price assumes the brand keeps its relevance rather than fading the way footwear fads historically have.

HEYDUDE is the evidence that this risk is real, not theoretical. Crocs bought HEYDUDE near a peak and has since written it down hard, recording a "$430.0 million" trademark impairment in the second quarter of 2025, with the company concluding "the estimated fair value of the trademark did not exceed its carrying value." HEYDUDE brand revenue fell 13% in the first quarter, with wholesale down 26%. An acquisition that destroyed several hundred million dollars of value is a direct demonstration of the peak-versus-sustainable problem, and it is fair to ask whether the core Crocs brand, also riding strong demand, carries the same latent risk on a larger base.

Tariffs and North America add the near-term pressure. Adjusted gross margin fell 90 basis points in the first quarter, with about 100 basis points of that the direct impact of incremental tariffs, and North America, still the larger market today, is in decline. On the valuation, the methods split in the value-trap pattern: the relative-multiple and cash-flow methods say cheap, but the asset-value methods say expensive, because the return on equity has been depressed by the writedowns. State the requirement plainly: the case rests on the trough operating margin near 3% reverting toward the company's through-cycle 13%, and if international growth fails to offset North American maturation, or if the Crocs brand follows HEYDUDE into a fashion downcycle, the margin does not fully revert and the stock is cheap for a reason. The balance sheet is sound, net debt around $1.2 billion with interest covered six times and real free cash flow, so this is not distress. It is a cyclical brand business priced for a recovery the demand trend has not yet confirmed.

Valuation

The honest way to value Crocs is on its normal margins, not this year's depressed ones, because the trailing operating margin near 3% is the product of a large non-cash writedown rather than the underlying economics. On the company's own through-the-cycle margin applied to current revenue, the price pays about 15 times mid-cycle operating income, which the model reads as implying roughly 24.6% annual operating growth for five years. That figure looks demanding, but it is inflated by the fact that revenue is currently flat to slightly declining; the real bet is margin reversion, not a high growth rate. Only about 35% of comparable fast-growers sustained a pace like that, so treat the implied number as a directional flag rather than a forecast.

The methods we use to triangulate sort into the classic value-versus-trap split. The relative-multiple comparison against the footwear sector lands well above the price, calling it cheap. The cash-flow methods, capitalizing the roughly $640 million of free cash flow, land near or above the price. But the asset-value methods land far below it, because the return on equity has been hammered by the HEYDUDE impairment and book value alone does not support the price. The spread is the whole debate: value the company on its cash generation and it looks cheap; value it on its current returns on capital and it does not. Which lens is right depends entirely on whether the margin is a trough or a new normal.

Solvency is sound and keeps the downside bounded. Net debt of about $1.2 billion is real but interest is covered roughly six times, the company is generating substantial free cash flow rather than burning it, and the falling share count shows that cash returning to holders. The downside is bounded by a cash-generative core brand and a clean-enough balance sheet, not by net cash. What the price is really weighing is durability: whether the Crocs brand holds its cultural relevance and international momentum long enough for the consolidated margin to revert, and whether HEYDUDE stops detracting from it.

Catalysts

The clearest catalyst is the international growth handoff. Management expects international revenue to surpass North America in 2026, targeting roughly 10% international growth led by China, where the company has leaned into local platforms like Douyin, and supported by up to 250 new stores worldwide. International Crocs brand revenue already grew 7% in the first quarter against a 6% North American decline, so the pace of that international ramp is the cleanest read on whether the core brand's growth runway is real.

The HEYDUDE turnaround is the second catalyst. After the impairments, the brand's direct-to-consumer revenue rose 8% in the first quarter and management improved full-year HEYDUDE guidance to a 5% to 7% decline from a steeper drop. Evidence that HEYDUDE has stopped detracting, and eventually returns to growth, is what lets the consolidated margin revert toward its through-cycle level, so each quarter's HEYDUDE trajectory is a swing factor for the whole thesis.

Tariffs and capital return frame the rest. Incremental tariffs cost about 100 basis points of gross margin in the first quarter, and how much Crocs can offset through pricing, sourcing, and mix is a live question for 2026 profitability. Against that, the company keeps repurchasing stock at a depressed multiple. Analyst sentiment leans constructive, with a Buy consensus and targets ranging from the low $70s to as high as $150 after a recent upgrade, a spread that captures the value-versus-trap disagreement. The next earnings print is the test of whether international growth and the HEYDUDE reset are tracking the guided second-half recovery.

Peer Cohorts (Per Segment, With Filing Citations)

Crocs Brand (reported)

HEYDUDE Brand (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

CROX FY2025 10-K, accession 0001334036-26-000006 · Crocs 2026 guidance · Crocs Q1 2026 results · CROX solvency, latest filings · analyst notes, 2026

View the full interactive CROX report on boothcheck